PriceTargets.com logo

Immunocore - IMCR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $56.38
  • Forecasted Upside: 84.90%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$30.49 As of 10/30/2026 05:00 PM ET
▼ -0.78 (-2.49%)

This chart shows the closing price for IMCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunocore Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMCR

Analyst Price Target is $56.38
▲ +84.90% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Immunocore in the last 3 months. The average price target is $56.38, with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 84.90% upside from the last price of $30.49.

This chart shows the closing price for IMCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Immunocore. This rating has held steady since August 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/26/2026HC WainwrightReiterated RatingBuy ➝ Buy$100.00
10/15/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/3/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/24/2026TD CowenUpgradeStrong-Buy
8/21/2026JPMorgan Chase & Co.Initiated CoverageOverweight$50.00
8/7/2026Morgan StanleySet Target$43.00
8/5/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
8/3/2026MizuhoBoost TargetNeutral ➝ Neutral$34.00 ➝ $35.00
7/17/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/13/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
7/7/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
5/7/2026Zacks ResearchUpgradeStrong Sell ➝ Strong-Buy
4/27/2026Zacks ResearchDowngradeHold ➝ Strong Sell
4/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
4/20/2026HC WainwrightReiterated RatingBuy ➝ Buy$100.00
4/14/2026HC WainwrightReiterated RatingBuy ➝ Buy$100.00
3/16/2026Jefferies Financial GroupDowngradeBuy ➝ Hold$48.00 ➝ $33.00
2/26/2026Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $75.00
2/25/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
2/19/2026MizuhoSet Target$38.00
2/4/2026HC WainwrightReiterated RatingBuy ➝ Buy$100.00
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/7/2026UBS GroupSet TargetSell ➝ Buy$24.00 ➝ $55.00
1/7/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
1/7/2026UBS GroupUpgradeSell ➝ Buy$24.00 ➝ $55.00
11/10/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$34.00 ➝ $36.00
10/31/2025Wells Fargo & CompanyInitiated CoverageOverweight$60.00
10/31/2025Wells Fargo & CompanyInitiated CoverageOverweight$60.00
10/22/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/18/2025GuggenheimInitiated CoverageNeutral
9/4/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/25/2025Jefferies Financial GroupInitiated CoverageBuy$48.00
6/2/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00
5/27/2025Deutsche Bank AktiengesellschaftInitiated CoverageBuy$65.00
5/8/2025OppenheimerBoost TargetOutperform ➝ Outperform$85.00 ➝ $86.00
4/14/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$54.00 ➝ $50.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00
4/7/2025MizuhoLower TargetNeutral ➝ Neutral$38.00 ➝ $33.00
3/12/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00
3/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
3/7/2025Morgan StanleyReiterated RatingEqual Weight$35.00 ➝ $35.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
2/27/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00
1/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
1/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00
12/13/2024Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$74.00 ➝ $35.00
11/11/2024MizuhoDowngradeOutperform ➝ Neutral$72.00 ➝ $38.00
11/7/2024Needham & Company LLCLower TargetBuy ➝ Buy$78.00 ➝ $71.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
10/24/2024UBS GroupInitiated CoverageSell$24.00
10/11/2024Morgan StanleyLower TargetOverweight ➝ Overweight$80.00 ➝ $74.00
10/7/2024GuggenheimDowngradeBuy ➝ Neutral
9/17/2024Needham & Company LLCLower TargetBuy ➝ Buy$81.00 ➝ $78.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
8/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
8/9/2024OppenheimerReiterated RatingOutperform ➝ Outperform$87.00 ➝ $89.00
8/9/2024BarclaysLower TargetOverweight ➝ Overweight$92.00 ➝ $66.00
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00
7/10/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$70.00 ➝ $66.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
6/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00
5/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00
5/13/2024MizuhoLower TargetBuy ➝ Buy$90.00 ➝ $88.00
5/9/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$63.00 ➝ $67.00
5/9/2024HC WainwrightBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
4/29/2024Leerink PartnersReiterated RatingOutperform
4/29/2024Leerink PartnersInitiated CoverageOutperform$74.00
4/23/2024GuggenheimReiterated RatingBuy ➝ Buy$92.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
3/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$60.00 ➝ $70.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/5/2024MizuhoBoost TargetBuy ➝ Buy$86.00 ➝ $90.00
2/29/2024OppenheimerReiterated RatingOutperform ➝ Outperform$85.00 ➝ $87.00
2/29/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$60.00 ➝ $63.00
2/29/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
2/16/2024MizuhoBoost TargetBuy ➝ Buy$72.00 ➝ $86.00
11/20/2023JPMorgan Chase & Co.Reiterated RatingOverweight$60.00
11/2/2023Cantor FitzgeraldInitiated CoverageOverweight
10/31/2023Robert W. BairdInitiated CoverageOutperform$84.00
9/21/2023OppenheimerBoost TargetOutperform ➝ Outperform$75.00 ➝ $85.00
9/13/2023Needham & Company LLCInitiated CoverageBuy$75.00
9/13/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$22.00
8/23/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/16/2023Capital One FinancialInitiated CoverageOverweight$84.00
8/11/2023BTIG ResearchBoost TargetBuy ➝ Buy$85.00 ➝ $91.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/11/2023OppenheimerBoost TargetOutperform ➝ Outperform$72.00 ➝ $75.00
7/31/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$79.00
7/24/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$79.00
7/17/2023Canaccord Genuity GroupInitiated CoverageHold$67.00
5/11/2023MizuhoBoost Target$70.00 ➝ $74.00
4/19/2023HC WainwrightReiterated RatingBuy$90.00
3/30/2023MizuhoInitiated CoverageBuy$70.00
3/30/2023GuggenheimInitiated CoverageBuy$85.00
3/24/2023Bryan, Garnier & CoInitiated CoverageBuy$16.00
3/8/2023HC WainwrightReiterated RatingBuy$90.00
2/15/2023OppenheimerBoost TargetOutperform$65.00 ➝ $72.00
12/16/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$33.00 ➝ $80.00
11/30/2022BarclaysInitiated CoverageOverweight$80.00
11/21/2022HC WainwrightBoost TargetBuy$80.00 ➝ $90.00
11/10/2022Morgan StanleyBoost TargetOverweight$72.00 ➝ $79.00
10/13/2022Morgan StanleyLower TargetOverweight$77.00 ➝ $72.00
9/14/2022JPMorgan Chase & Co.Boost TargetOverweight$60.00 ➝ $67.00
9/9/2022Morgan StanleyInitiated CoverageOverweight$77.00
9/8/2022LADENBURG THALM/SH SHInitiated CoverageBuy$82.00
8/8/2022TD CowenInitiated CoverageOutperform$70.00
8/2/2022BTIG ResearchInitiated CoverageBuy$85.00
7/5/2022HC WainwrightReiterated RatingBuy$80.00
2/8/2022HC WainwrightInitiated CoverageBuy$80.00
(Data available from 10/30/2021 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Immunocore logo
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $30.49
Low: $30.13
High: $31.44

50 Day Range

MA: $32.48
Low: $27.82
High: $37.57

52 Week Range

Now: $30.49
Low: $27.50
High: $40.71

Volume

290,233 shs

Average Volume

531,374 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunocore?

The following Wall Street sell-side analysts have issued stock ratings on Immunocore in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, TD Cowen, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for IMCR.

What is the current price target for Immunocore?

0 Wall Street analysts have set twelve-month price targets for Immunocore in the last year. Their average twelve-month price target is $56.38, suggesting a possible upside of 81.4%. HC Wainwright has the highest price target set, predicting IMCR will reach $100.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $33.00 for Immunocore in the next year.
View the latest price targets for IMCR.

What is the current consensus analyst rating for Immunocore?

Immunocore currently has 1 sell rating, 4 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IMCR.

What other companies compete with Immunocore?

Other companies that are similar to Immunocore include Oruka Therapeutics, Rhythm Pharmaceuticals, Ligand Pharmaceuticals, Immunovant and Kodiak Sciences. Learn More about companies similar to Immunocore.

How do I contact Immunocore's investor relations team?

Immunocore's physical mailing address is 92 Park Drive, Abingdon, OX, OX14 4RY. The company's listed phone number is 44-12-3543-8600 and its investor relations email address is [email protected]. The official website for Immunocore is www.immunocore.com. Learn More about contacing Immunocore investor relations.